Fusion Gene Promotes Growth of Malignant Cutaneous Angiosarcoma

Its five-year survival rate is only 20%–30%, so new diagnostic and therapeutic approaches are urgently required.

Investigators at Kumamoto University (Japan) and Kitasato University (Tokyo, Japan) used transcriptome sequencing—the analysis of the library of genes being actively read and transcribed by a cell—from patient-derived angiosarcoma cells (ISO-HAS) to search for chromosome rearrangements.

They reported in the November 1, 2015, online edition of the journal Cancer Research that they had identified a novel fusion gene NUP160–SLC43A3 that was expressed in 9 of 25 human angiosarcoma specimens that were examined. In tumors harboring the fusion gene, the duration between the onset of symptoms and the first hospital visit was significantly shorter, suggesting more rapid tumor progression.

Cancer cells expressing the fusion gene were implanted subcutaneously into immunodeficient mice. By the end of five weeks, the implants had induced formation of tumors in the mice that were similar to human angiosarcoma.

"The identification of this novel fusion gene has potential implications for new diagnostic and therapeutic approaches for this area of cancer research," said contributing author Dr. Masatoshi Jinnin, associate professor of dermatology and plastic surgery at Kumamoto University. "Furthermore, earlier hospital visits by these patients often means that the disease has not yet metastasized. Their prognosis can be improved by implementing appropriate treatments immediately after diagnosis."

Related Links:
Kumamoto University
Kitasato University